Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setidegrasib in KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma
NCT07409272Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Feb 2026
- Primary completion
- Aug 2029
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 11
01
Overview
A Phase 3 trial of setidegrasib in pancreatic adenocarcinoma (PDAC), sponsored by Astellas Pharma. Started Feb 2026; status: recruiting.
02
Drugs
setidegrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07409272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07409272.